Burger line Burger line Burger line
Logo Logo Logo
Burger line Burger line Burger line
Menu
Sign in
Sign in

Sumitomo Pharma’s Ewing Sarcoma Candidate Gains Orphan Drug Status

Sumitomo Pharma’s Ewing Sarcoma Candidate Gains Orphan Drug Status

Sumitomo Pharma Oncology has received FDA’s Orphan Drug designation for its TP-1287 candidate to treat Ewing sarcoma, a rare cancer that typically occurs in children or teenagers.

TP-1287 is an oral CDK9 protein inhibitor, which has been shown to inhibit tumor growth in preclinical models of blood cancers and several tumor types.

The drug candidate is being evaluated in a phase 1 study in patients with advanced metastatic or progressive solid tumors who are either resistant to or can’t tolerate the standard therapy.

TP-1287 has previously received the FDA’s Rare Pediatric Disease designation.

April 12, 2023

https://www.fdanews.com/

0 items in Cart
Cart Subtotal:
Go to cart
You will be able to Pay Online or Request a Quote
Catalog
Services
Company

We use "cookies*  to ensure the functionality of our website, recognise your browser or device, learn more about your interests, and provide you with essential features and services and for additional purposes, including:

Recognising you when you sign-in to use our services. This allows us to provide you with product recommendations, display personalised content, and provide other customised features and services.
Keeping track of your specified preferences. You may set your preferences through Your Account..
Keeping track of items stored in your shopping basket and personal cabinet.
Conducting research and diagnostics to improve ChemDiv’s content, products, and services.
Delivering content, including ads, relevant to your interests on ChemDiv’s site
Reporting. This allows us to measure and analyse the performance of our services.

By  cookies you give consent to the processing of your personal data, including transfer to third parties. Further information can be found in our privacy policy.

Accept all cookies